33 patents
Page 2 of 2
Utility
Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant
2 Sep 21
Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat.
Vasu Sethuraman, David Bruce HEDDEN, Kristen Marie LESKOW
Filed: 7 May 21
Utility
CorrectedMethod of Generating Anti-Linaclotide Antibodies and Uses Thereof
26 Aug 21
The invention provides a method for producing anti-linaclotide antibodies or antigen fragments thereof and uses thereof.
Wilmin Bartolini, Marco Kessler
Filed: 9 May 19
Utility
Treatments for Gastrointestinal Disorders
4 Feb 21
The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
Filed: 9 Oct 20
Utility
Gastro-retentive Sustained-release Oral Dosage Form of a Bile Acid Sequestrant
21 Jan 21
Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat.
Vasu Sethuraman, David Bruce HEDDEN, Kristen Marie LESKOW
Filed: 30 Sep 20
Utility
Treatments for Gastrointestinal Disorders
9 Sep 20
The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Angelika Fretzen, Hong Zhao, Marco Kessler
Filed: 21 May 20
Utility
Method of Generating Anti-Linaclotide Antibodies and Uses Thereof
13 May 20
The invention provides a method for producing anti-linaclotide antibodies or antigen fragments thereof and uses thereof.
Wilmin Bartolini, Marco Kessler
Filed: 8 May 19
Utility
Method of Detecting and Quantifying Bile Acid from Saliva
6 May 20
A method of detecting and quantifying bile acids from saliva from a human patient; the method involves collecting saliva from the patient and determining the bile acid levels in the saliva, using, for example, liquid chromatography with tandem mass spectrometry.
Mark G. Currie, Nisha Lizan Perez
Filed: 18 Jul 18
Utility
Methods of Treating Upper Gastrointestinal Disorders In Ppi Refractory Gerd
15 Apr 20
Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD.
Bernard Joseph Lavins, Mark G. Currie
Filed: 27 May 19
Utility
Low-Dose Stable Formulations of Linaclotide
5 Feb 20
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Yun Mo, Carolline Kurtz
Filed: 10 Sep 19
Utility
Stable Formulations of Linaclotide
29 Jan 20
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
YUN MO, ANGELIKA FRETZEN, BRIAN CALI, MAHENDRA DEDHIYA
Filed: 25 Sep 19
Utility
Stable Formulations of Linaclotide
8 Jan 20
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Yun Mo, Angelika Fretzen, Brian Cali, Mahendra Dedhiya
Filed: 18 Sep 19
Utility
Modified or Targeted Release Formulations of Linaclotide
20 Nov 19
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Ahmad Hashash
Filed: 29 Jul 19
Utility
SGC Stimulators
13 Nov 19
Charles Kim, Takashi Nakai, Thomas Wai-Ho Lee, Joel Moore, Nicholas Robert Perl, Jason Rohde, Rajesh R. Iyengar, Ara Mermerian, Angelika Fretzen
Filed: 3 Dec 18